Table 1.
Characteristics of the Participants
| Characteristic | All (n=174) | AC (n=57) | LET (n=58) | NLET (n=59) |
|---|---|---|---|---|
| Time (yrs) from completion of primary cancer treatment to enrollment – mean (SD) | 2.8 (1.3) | 2.7 (1.2) | 2.9 (1.1) | 2.8 (1.5) |
| Age (yrs) – mean (SD) | 58 (9) | 58 (9) | 59 (9) | 58 (9) |
| BMI (kg/m2) – mean (SD) | 29.5 (5.6) | 29.1 (5.2) | 30.1 (6.0) | 29.2 (5.6) |
| Exercise behavior (minutes/week)* – mean (SD) | 52.0 (103.6) | 43.6 (101.3) | 46.4 (113.4) | 65.6 (96.0) |
| Left ventricular ejection fraction (%) – mean (SD) | 62 (5) | 63 (5) | 63 (5) | 62 (4) |
| Study Site – no. (%) | ||||
| DUMC | 115 (66) | 38 (67) | 38 (66) | 39 (66) |
| MSK | 59 (34) | 19 (33) | 20 (35) | 20 (34) |
| Race – no. (%) | ||||
| Non-Hispanic white | 109 (63) | 35 (61) | 36 (62) | 38 (64) |
| Other group | 65 (37) | 22 (39) | 22 (38) | 21 (36) |
| Smoking – no. (%) | ||||
| Never | 106 (61) | 31 (54) | 37 (64) | 38 (64) |
| Former | 58 (33) | 22 (39) | 18 (31) | 18 (31) |
| Current | 10 (6) | 4 (7) | 3 (5) | 3 (5) |
| Disease stage – no. (%) | ||||
| I | 99 (57) | 32 (56) | 32 (55) | 35 (59) |
| II | 60 (35) | 22 (39) | 19 (33) | 19 (32) |
| III | 14 (8) | 3 (5) | 6 (10) | 5 (9) |
| Clinical subtype – no. (%) | ||||
| ER+/PR+ | 109 (63) | 40 (70) | 31 (53) | 38 (64) |
| HER2+ | 34 (20) | 10 (18) | 14 (24) | 10 (17) |
| ER−/PR−/HER2− | 30 (17) | 6 (12) | 13 (22) | 11 (19) |
| Adjuvant therapy – no. (%) | ||||
| Surgery | ||||
| Lumpectomy | 87 (50) | 30 (53) | 26 (45) | 31 (53) |
| Mastectomy | 87 (50) | 27 (47) | 32 (55) | 28 (48) |
| Chemotherapy– no. (%) | 102 (59) | 34 (60) | 33 (57) | 35 (59) |
| Anthracycline-containing* | 66 (65) | 21 (62) | 19 (58) | 26 (74) |
| Herceptin* | 24 (24) | 6 (18) | 10 (30) | 8 (23) |
| Radiotherapy – no. (%) | 123 (71) | 40 (70) | 38 (66) | 45 (76) |
| Left-sided | 65 (53) | 20 (50) | 22 (58) | 23 (51) |
| Endocrine therapy – no. (%) | 123 (71) | 39 (68) | 40 (69) | 44 (75) |
| Tamoxifen | 46 (37) | 12 (31) | 18 (45) | 16 (36) |
| Aromatase inhibitor | 85 (69) | 30 (77) | 25 (63) | 30 (68) |
| Current Medications | ||||
| Beta-blockers | 26 (15) | 8 (14) | 12 (21) | 6 (10) |
| ACE inhibitors | 22 (13) | 7 (12) | 8 (14) | 7 (12) |
| Angiotensin receptor blockers | 18 (10) | 8 (14) | 4 (7) | 6 (10) |
| Diuretic | 39 (22) | 11 (19) | 19 (33) | 9 (15) |
| Aspirin/Anti-Platelet | 38 (22) | 14 (25) | 13 (22) | 11 (19) |
| Statins | 40 (23) | 12 (21) | 13 (22) | 15 (25) |
| Calcium Channel Blocker | 16 (9) | 5 (9) | 7 (12) | 4 (7) |
| Pre-existing (controlled) cardiovascular conditions – no. (%) | ||||
| Coronary artery disease | 4 (2) | 1 (2) | 1 (2) | 2 (3) |
| Osteoporosis | 16 (9) | 2 (4) | 7 (12) | 7 (12) |
| Arthritis | 34 (20) | 14 (25) | 12 (21) | 8 (14) |
| Type II diabetes | 23 (13) | 10 (18) | 5 (9) | 8 (14) |
| Hyperlipidemia | 29 (17) | 9 (16) | 8 (14) | 12 (20) |
| Hypertension | 76 (44) | 27 (47) | 28 (48) | 21 (36) |
| Any | 102 (59) | 35 (61) | 37 (64) | 30 (51) |
All comparisons p>0.05
*
Exercise behavior defined as the total minutes of self-reported moderate/vigorous exercise per week.
Chemotherapy, radiation, and endocrine therapy rates include only those patients receiving each treatment.
Abbreviations: AC, attention control; LET, standard linear exercise training; NLET, non-linear exercise training; SD, standard deviation; DUMC, Duke University Medical Center; MSK, Memorial Sloan Kettering; BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blockers.